RxDoctor Payments Data

Nicholas Sorrel, MD

Otolaryngology · Thibodaux, LANPI 1700131950

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,288 of the $5,278 with a category attached, or 62.3%. 23 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 26.1% of the total.

$5,278in general payments, 2019–2025

Across 101 payments — averaging $52.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Aerin Medical Inc.$1K
  • Acclarent, Inc$791
  • Medtronic$585
  • Sanofi$334
  • Optinose US, Inc.$256
  • plus $882 from 17 others

What the payments were for

  • Consulting fees$1,00019%
  • Travel & lodging$99019%
  • Food & beverage$3,28862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,278 in reported general payments places this provider in the 85th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$365,131
Medicare patients
490
Services billed
7,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl473$12,801
Fluticasone Propionate515$6,674
Epinephrine14$3,365
Cefdinir106$2,077
Ipratropium Bromide86$2,077
Ofloxacin70$1,961
Doxycycline Hyclate75$1,103
Prednisolone Acetate27$813
Mupirocin38$758
Methylprednisolone74$553
Famotidine66$535
Amitriptyline Hcl38$521
Omeprazole57$518
Gentamicin Sulfate19$451
Prednisone135$383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$16$3,36514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →